Windy with rain and snow showers this evening transitioning to snow showers overnight. Low 32F. Winds WSW at 20 to 30 mph. Chance of precip 50%. Winds could occasionally gust over 40 mph..
Windy with rain and snow showers this evening transitioning to snow showers overnight. Low 32F. Winds WSW at 20 to 30 mph. Chance of precip 50%. Winds could occasionally gust over 40 mph.
Updated: January 19, 2023 @ 6:10 pm
Aligos Therapeutics Inc (NQ: ALGS )
1.115 +0.005 (+0.45%) Streaming Delayed Price Updated: 4:00 PM EDT, Mar 29, 2023 Add to My Watchlist
All News about Aligos Therapeutics Inc
A Preview Of Aligos Therapeutics's Earnings
March 08, 2023
Aligos Co-Founders File Complaint Against Johnson & Johnson Alleging Fraud
September 29, 2022
Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023
February 28, 2023
12 Health Care Stocks Moving In Monday's After-Market Session
January 16, 2023
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 17, 2023
Gainers Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program...
12 Health Care Stocks Moving In Friday's Intraday Session
January 06, 2023
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
January 06, 2023
Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022
November 04, 2022
Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase 1 study ALG-000184-201
SVB Leerink Maintains Market Perform Rating for Aligos Therapeutics: Here's What You Need To Know
November 03, 2022
SVB Leerink has decided to maintain its Market Perform rating of Aligos Therapeutics (NASDAQ:ALGS) and lower its price target from $3.00 to $2.00. Shares of Aligos Therapeutics are trading up 0.0% over...
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
October 18, 2022
Aligos’ pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following